title: Treatment of severe cancer pain by low-dose continuous subcutaneous morphine.
abstract: In a prospective and intraindividually controlled trial, we have compared the efficacy and safety of a continuous subcutaneous morphine infusion with conventional intermittent oral or subcutaneous morphine application. Twenty-eight in-patients with cancer pain received a short-term infusion lasting 2-42 days, and 8 out-patients underwent long-term infusion from 49 to 197 days during the terminal stage of their disease. Continuous subcutaneous morphine infusion significantly (P less than 0.001) improved both pain and quality of life when compared to conventional morphine application. With continuous infusion, 5-48 mg (median 19 mg) of morphine was required daily, significantly (P less than 0.001) less than the 10-90 mg (median 50 mg) necessary with conventional use. As a result of lower dosage, side effects under continuous infusion were infrequent and mild. Constipation occurred in 3 of the 36 patients and was always controlled by the addition of laxatives; no nausea, sedation or respiratory depression were observed. Signs of tolerance developed in 2 patients on long-term infusion, but the use of continuous subcutaneous methadone for 2 weeks reversed the tolerance. The study presented indicates that low-dose continuous subcutaneous morphine provides a valuable treatment modality for severe terminal cancer pain exhibiting a high degree of both efficacy and safety.
authors: Department of Medicine, Diabetes and Lipid Metabolism Division, University of Innsbruck, InnsbruckAustria Department of Medicine, City Hospital, DornbirnAustria.
authors: Heinz
authors: H
authors: Drexel
authors: Alexander
authors: A
authors: Dzien
authors: Robert W
authors: RW
authors: Spiegel
authors: Alois H
authors: AH
authors: Lang
authors: Christoph
authors: C
authors: Breier
authors: Klaus
authors: K
authors: Abbrederis
authors: Josef R
authors: JR
authors: Patsch
authors: Herbert
authors: H
authors: Braunsteiner
mesh_terms: D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D004361:Drug Tolerance; D006801:Humans; D007260:Infusion Pumps; D009020:Morphine / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D009369:Neoplasms / Q000188:drug therapy; D010147:Pain Measurement; D010166:Palliative Care
chemical_list: D009020:Morphine